Filana Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Filana Therapeutics, Inc. (FLNA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.68 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-12
- Filana Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.68, a 93.70% decline from fiscal 2024.
- Filana Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $26.65, a 40.93% increase from fiscal 2023.
- Filana Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $18.91, a 48.19% decline from fiscal 2022.
- Filana Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $36.50, a 47.25% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $1.68 10-K · filed 2026-03-12 |
| 2024-12-31 | $26.65 10-K · filed 2025-03-03 |
| 2023-12-31 | $18.91 10-K · filed 2024-02-28 |
| 2022-12-31 | $36.50 10-K · filed 2023-02-28 |
| 2021-12-31 | $69.20 10-K · filed 2022-03-01 |
| 2020-12-31 | $7.25 10-K · filed 2021-03-23 |
| 2019-12-31 | $1.80 10-K · filed 2020-03-26 |
| 2018-12-31 | $1.43 10-K · filed 2019-03-29 |
| 2017-12-31 | $3.68 10-K · filed 2018-02-06 |
| 2016-12-31 | $2.36 10-K · filed 2017-03-07 |
| 2015-12-31 | $1.90 10-K · filed 2016-03-03 |
| 2014-12-31 | $3.45 10-K · filed 2015-02-18 |
| 2013-12-31 | $2.44 10-K · filed 2014-02-05 |
| 2012-12-31 | $4.19 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |